Anaplastic lymphoma kinase gene mutation – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:12:58 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Anaplastic lymphoma kinase gene mutation – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study Comparing Alectinib and Crizotinib for Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer https://clinicaltrials.eu/trial/study-comparing-alectinib-and-crizotinib-for-patients-with-alk-positive-advanced-non-small-cell-lung-cancer/ Wed, 29 Apr 2026 15:01:48 +0000 https://clinicaltrials.eu/trial/study-comparing-alectinib-and-crizotinib-for-patients-with-alk-positive-advanced-non-small-cell-lung-cancer/ This clinical trial is focused on studying a type of lung cancer known as Anaplastic Lymphoma Kinase (ALK)-positive non-small cell lung cancer (NSCLC). This is a specific form of lung cancer where the cancer cells have a change in the ALK gene, which can promote cancer growth. The study is comparing two treatments: Alectinib (Alecensa) and Crizotinib. Both of these medications are taken orally in the form of hard capsules and are designed to target and inhibit the activity of the ALK protein, which is involved in the growth of cancer cells.

The purpose of the study is to evaluate and compare the effectiveness of Alectinib and Crizotinib in patients who have not received prior treatment for their advanced ALK-positive NSCLC. Participants in the study will be randomly assigned to receive either Alectinib or Crizotinib. The study will monitor how long the cancer is controlled without worsening, which is known as progression-free survival. Other aspects such as overall survival, quality of life, and any side effects will also be observed.

Throughout the study, participants will undergo regular check-ups and assessments to track their health and the cancer’s response to the treatment. The study aims to provide valuable information on which medication might be more effective for patients with this specific type of lung cancer. The trial is expected to continue until 2026, allowing researchers to gather comprehensive data on the long-term effects and benefits of these treatments.

]]> Study of Alectinib and Platinum-Based Chemotherapy for Patients with Resected Stage Ib to IIIa ALK-Positive Non-Small Cell Lung Cancer https://clinicaltrials.eu/trial/56719/ Wed, 29 Apr 2026 14:29:15 +0000 https://clinicaltrials.eu/trial/56719/ The study focuses on patients with a type of lung cancer known as non-small cell lung cancer (NSCLC), specifically when this cancer has a certain genetic marker called ALK-positive. The stages of cancer involved range from Stage Ib, with tumors at least 4 centimeters, to Stage IIIa. This trial looks at how well two different treatments work after the cancer has been surgically removed: a drug named Alectinib and a group of drugs known as platinum-based chemotherapy.

Alectinib is provided in capsule form and taken orally. It belongs to a group of drugs that target specific cancer cells with the ALK marker, aiming to stop their growth and spread. Platinum-based chemotherapy involves medications like Carboplatin, Cisplatin, and Pemetrexed, which are given through an infusion, meaning they are administered directly into the bloodstream. This form of chemotherapy uses drugs that contain the metal platinum, which helps to damage the DNA of cancer cells, preventing them from dividing and growing.

The purpose of this study is to compare how effectively these treatments prevent cancer from returning in patients who have already had their tumors removed. By looking at which treatment helps patients remain cancer-free for a longer period, the study aims to determine the better option for use after surgery in this specific type of lung cancer.

]]>